THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION No. 1089 Session of 2018

INTRODUCED BY R. BROWN, BIZZARRO, BOBACK, BURNS, CALTAGIRONE, SCHLEGEL CULVER, DIGIROLAMO, DRISCOLL, DUSH, HENNESSEY, HILL-EVANS, KAVULICH, LONGIETTI, MEHAFFIE, MILLARD, MUSTIO, NEILSON, READSHAW, RYAN, SONNEY, YOUNGBLOOD AND WARREN, SEPTEMBER 25, 2018

INTRODUCED AS NONCONTROVERSIAL RESOLUTION UNDER RULE 35, SEPTEMBER 25, 2018

A RESOLUTION

1 2	Recognizing the month of September 2018 as "Polycystic Kidney Disease Awareness Month" in Pennsylvania.
3	WHEREAS, Polycystic kidney disease (PKD) is a genetic disease
4	that is passed from an infected parent to child and causes
5	uncontrolled growth of cysts in the kidney; and
6	WHEREAS, PKD affects all racial and ethnic groups equally and
7	occurs equally in men and women; and
8	WHEREAS, Approximately 600,000 people in the United States
9	have PKD and it is the fourth leading cause of kidney failure;
10	and
11	WHEREAS, There are three types of PKD: autosomal dominant
12	(ADPKD), autosomal recessive (ARPKD) and acquired cystic (ACKD);
13	and
14	WHEREAS, ADPKD is the most common form of PKD, comprising
15	90% of all PKD cases, and it is passed from parent to child
16	genetically by dominant inheritance; and

1 WHEREAS, Symptoms of ADPKD typically begin between 30 and 40 2 years of age, but can begin as early as childhood; and 3 WHEREAS, ARPKD is passed from parent to child genetically by recessive inheritance; and 4 WHEREAS, ARPKD is a rare form of PKD and occurs in 1 in 5 6 20,000 children worldwide; and 7 WHEREAS, Symptoms of ARPKD begin in the earliest months of 8 life, even in the womb; and 9 WHEREAS, ARPKD is very serious because it progresses rapidly and is often fatal in the first few months of life; and 10 11 WHEREAS, ACKD is most often associated with kidney failure and dialysis because it can cause long-term damage and severe 12 13 scarring in the kidney; and

14 WHEREAS, ACKD develops in about 90% of people who have been 15 on dialysis for at least five years; and

16 WHEREAS, Symptoms that may indicate that an individual has 17 PKD include back or side pain, an increase in the size of the 18 abdomen, blood in the urine, frequent bladder or kidney 19 infections, fluttering or pounding in the chest and high blood 20 pressure; and

21 WHEREAS, High blood pressure is the most common sign of PKD; 22 and

23 WHEREAS, If high blood pressure is treated, the treatment can 24 help slow or even prevent kidney failure; and

25 WHEREAS, Approximately 50% of individuals with PKD will have 26 kidney failure by 60 years of age, and 60% of individuals will 27 have kidney failure by 70 years of age; and

28 WHEREAS, The only options available for individuals 29 experiencing kidney failure are dialysis or a kidney transplant; 30 and

20180HR1089PN4057

- 2 -

1 WHEREAS, Although PKD has no cure, supportive treatments can 2 be administered to control symptoms, help slow cyst growth and 3 prevent or slow down the loss of kidney function as a result of 4 PKD; and

5 WHEREAS, Supportive treatments for PKD include all of the 6 following:

(1) Carefully controlling blood pressure.

8 (2) Promptly treating bladder or kidney infections with9 antibiotics.

10 (3) Drinking a lot of water when blood in the urine is 11 first noticed.

12

7

(4) Using medication to control pain.

(5) Maintaining a healthy lifestyle by quitting smoking,
exercising, controlling weight, avoiding caffeine and
reducing salt intake;

16 and

WHEREAS, The average annual cost per patient of dialysis treatments is \$89,000, and the average total annual cost of dialysis treatments is \$42 billion nationwide; therefore be it RESOLVED, That the House of Representatives recognize the month of September 2018 as "Polycystic Kidney Disease Month" in Pennsylvania.

- 3 -